Kura Oncology stock rises on CEO insider purchase

Kura Oncology Inc (NASDAQ:KURA) experienced a 5.4% increase in its stock price in after-hours trading on Monday, following an insider purchase by the company’s President and CEO, Troy Edward Wilson. Wilson acquired 100,000 shares at an average price of $11.12 per share, as reported by a Form 4 filing with the Securities and Exchange Commission.

This transaction, executed in multiple trades between $10.87 and $11.31, brought Wilson’s beneficial ownership to 379,194 shares, spread across three trusts and direct holdings. The insider purchase is often interpreted as a positive indicator by market participants, given the executives' typically privileged access to company information.

This development highlights Wilson's confidence in Kura Oncology’s future prospects and underscores the significance of his investment.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.